SENTI-202 / Senti Bio - LARVOL DELTA

First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data (AACR 2025) - P1 | "2 SENTI-202 Dose Levels (DLs): 1e9 & 1.5e9 CAR NK cells/dose & 2 Schedules: 3 or 5 doses/ 28-day Cycle (I on Days 0, 7, 14; & II on Days 0, 3, 7, 10, 14, respectively), following lymphodepletion (LD) with fludarabine and cytarabine are being evaluated. Preliminary PK profile is consistent with allogeneic NK cell therapies and CyTOF analyses reveal LSC killing & HSPC protection consistent with SENTI-202 Logic Gated Gene Circuit design. Dose finding is ongoing & additional data from pts in Schedule II will be reported."

Clinical data • First-in-human • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology • CD33

Strategic Financing Agreement (GlobeNewswire) - "In April 2026, Senti Bio entered into a securities purchase agreement with an affiliate of Celadon Partners SPV 24, pursuant to which Senti Biosciences, Inc., the Company’s wholly owned subsidiary, may issue up to $40 million aggregate principal amount of senior secured convertible notes in up to two tranches....The Company expects to use proceeds from the financing to support general corporate purposes and advance clinical and manufacturing activities for SENTI-202."

Financing • Acute Myelogenous Leukemia

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program (GlobeNewswire) - "The Company plans to implement a single-arm, multi-center pivotal trial intended to support potential SENTI-202 registration in patients with R/R AML. This study is expected to evaluate SENTI-202 administered following lymphodepletion (LD) chemotherapy in a patient population consistent with the Phase 1 trial population....In addition to the positive RMAT meeting, after conducting exploratory efficacy covariate analysis of the Phase 1 trial results, Senti has identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50% (7/14) of the patients achieving a cCR when they received any SENTI-202 doses manufactured from Donor X-characteristic-derived NK cells in Cycle 1 versus 12.5% (1/8) achieving a cCR when they received SENTI-202 manufactured from non-Donor X NK cells."

Commercial • FDA event • New trial • P1 data • Acute Myelogenous Leukemia

SENTI-202 CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML while protecting human HSC/HPCs from off-tumor toxicity in a humanized mouse model (AACR 2025) - P1 | "The bivalent CD33 OR FLT3 activating CAR targets 2 AML antigens, CD33 & FLT3, enabling targeting of AML stem cells & blasts (Gonzalez, 2023; Kaveri, 2024) and venetoclax-resistant AML cells (Muftuoglu, 2023). In conclusion, the SENTI-202 CD33 OR FLT3 NOT EMCN logic-gated gene circuit enables exceptional efficacy against AML while protecting HSC/HPCs from off-tumor toxicity, demonstrating the potential of SENTI-202 as a targeted and precise therapy for AML. SENTI-202 is currently in Phase 1 clinical development in patients with relapsed/refractory hematologic malignancies including AML (NCT06325748)."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • EMCN • FLT3 • HER-2 • IL15 • PTPRC

Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML (AACR 2024) - "Pretreatment of CD33/FLT3 negative AML cell lines with Ara-C resulted in upregulation of CD33 and FLT3 expression, sensitizing cells to robust SENTI-202-mediated killing, providing additional rationale for the use of Ara-C-based LD. In the presence of exogenous IL2, persistence, cytotoxicity, and serial killing activity of SENTI-202 were increased, supporting the use of low dose IL2 to further augment SENTI-202 clinical activity.Taken together, these results support the Phase 1 trial design of SENTI-202-101 in patients with R/R CD33 and/or FLT3 positive malignancies including AML, which uses Flu/Ara-C as LD followed by 3 weekly doses of SENTI-202 and includes the option of enrolling patients into cohorts that additionally receive low dose IL2 following SENTI-202 administration."

P1 data • Preclinical • Acute Myelogenous Leukemia • Oncology • CD33 • EMCN • FLT3 • IL15

First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Correlative data (AACR 2025) - P1 | "Interim flow cytometry & CyTOF analyses of patient PB & BM in SENTI-202-101 affirms the anti-leukemic effects of SENTI-202 in responding patients, as well as the repopulation of immune cell subpopulations post-treatment. The presence of EMCN+ HSPCs in responder BM, as well as repopulation of BM & PB hematopoietic subpopulations, is consistent with the pharmacodynamic action of the Logic Gate in SENTI-202 in sparing EMCN+ HSPCs while selectively killing CD33+ and/or FLT3+ AML tumor cells."

Clinical • First-in-human • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology • ADGRG1 • CD33 • CD34 • CD38 • EMCN • FLT3

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (The Manila Times) - "Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENTI-202 as the lead program generating positive clinical data, while continuing to refine and expand the capabilities of our Gene Circuit platform...General and administrative expenses were $5.8 million and $8.4 million for the quarter ended December 31, 2025 and 2024, respectively. "

Commercial • Acute Myelogenous Leukemia

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference (GlobeNewswire) - "The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in adults with relapsed/refractory acute myeloid leukemia (AML)."

P1 data • Acute Myelogenous Leukemia

SENTI-202-101: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: Senti Biosciences | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Feb 2026

Enrollment closed • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • CD33 • FLT3

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (GlobeNewswire) - "With enrollment now complete, the Company plans to have discussions with the U.S. Food and Drug Administration in the first half of 2026 regarding the potential for a pivotal, registration program of SENTI-202 in R/R AML as well as the evaluation of additional indications including newly diagnosed AML and pediatric AML."

Enrollment closed • FDA event • Acute Myelogenous Leukemia

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation (GlobeNewswire) - "Dr. Lu also discussed the new data from 20 patients (18 with evaluable responses) in its ongoing multinational, multicenter clinical trial of SENTI-202 in patients with relapsed or refractory AML that were recently presented at the American Society of Hematology (ASH) Annual Meeting in Orlando."

P1 data • Acute Myelogenous Leukemia

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action (ASH 2025) - P1 | "Three dose cohortswere evaluated and the recommended phase 2 dose (RP2D) was determined as 1.5×109 CAR+ SENTI-202cells/dose given on Days 0, 7, and 14 of a 28-day cycle following lymphodepletion with fludarabine andcytarabine, based on the totality of clinical and correlative data.Patients on study had differing mutational status and proteomics, as expected with this heterogenousdisease...These LSCs were predominantly in G0 phase of the cell cycle atbaseline and therefore expected to be resistant to chemotherapeutic agents like cytarabine.In patient PB samples collected serially post SENTI-202 treatment, the repopulation of T cells, NK cells,neutrophils, and other immune cells was confirmed by flow cytometry in responders...The presence of EMCN+ HSPCs in responder BM, as well as repopulationof BM and PB hematopoietic subpopulations, is consistent with the pharmacodynamic action of theSENTI-202 Logic Gate in sparing EMCN+ HSPCs while selectively killing CD33+..."

Clinical • IO biomarker • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ADGRG1 • CD33 • CD34 • CD38 • EMCN • FLT3

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (ASH 2025) - P1 | "The study is designed to evaluate 2 Dose Levels (DLs) of SENTI-202 (1x109 & 1.5x109 CAR+ NKcells/dose) and 2 Dose Schedules (Sch) [Days 0, 7, 14 (Sch-I) or Days 0, 3, 7, 10, 14 (Sch-II)] followinglymphodepletion (LD) with fludarabine (30 mg/m2/day) and cytarabine (Ara-C) (2 g/m2/day) on Days -7 to -3...All pts received prior chemotherapy including Ara-C and 10 pts receivedprior venetoclax...Pharmacodynamic bone marrow cell population data were consistent with clinical responsesand SENTI-202's mechanism of action, i.e. reduction of blasts and LSCs along with preservation of HSPCsin cCR pts (additional details in separate Abstract ).Clinical data from the dose finding cohort of SENTI-202 in the ongoing Phase 1 trial reveals an excellentsafety profile for SENTI-202 administered after LD, and promising durable CRs (50% at RP2D, 42% overall,all MRD negative with median duration not reached and longest CR of 11+ mo). An expansion cohortenrolling R/R AML pts has..."

Clinical • P1 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Malignancies • Leukemia • Neutropenia • CD33 • EMCN • FLT3

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients… (GlobeNewswire) - "Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting....50% (6/12) of patients at the Recommended Phase 2 Dose (RP2D) and 50% (9/18) of all trial patients achieved an Overall Response Rate (ORR) outcome. 42% (5/12) of patients at the RP2D and 39% (7/18) of all patients overall achieved a Complete Remission (CR) or CR with Partial Hematologic Recovery (CRh). 100% of all CRs and ~80%+ of all responses were MRD negative. With limited follow-up in the RP2D cohort, the Kaplan-Meier estimate of median duration of composite Complete Remissions across all patients is 7.6 months (6.1, NE)."

P1 data • Acute Myelogenous Leukemia

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire) - "The FDA granted the RMAT designation based on data from the Company’s ongoing Phase 1 clinical trial of SENTI-202 in adult patients with relapsed or refractory (R/R) CD33 and/or FLT3 expressing hematologic malignancies, including AML."

FDA event • Acute Myelogenous Leukemia

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET (GlobeNewswire)

P1 data • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Sarah Cannon Research Institute to Present Research on Advances in Blood Cancers…at 2025 ASH Annual Meeting & Exposition (Sarah Cannon Research Institute (SCRI))

Clinical data • Acute Myelogenous Leukemia • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Myelodysplastic Syndrome • Waldenstrom Macroglobulinemia

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models (ASH 2023) - "Our initial PDX studies used clinically relevant VEN/HMA-r AML PDX cells (designated as PDX1) obtained from a patient with FLT3-ITD, GATA2, and NRAS mutations, who initially responded to VEN/decitabine treatment but later relapsed. In conclusion, CAR-NK cells expressing the SENTI-202 OR Gate and crIL15 demonstrate robust anti-tumor activity against primary AML cells within in vitro cytotoxicity assays and in vivo AML PDX models, including VEN-r AML. These promising preclinical results highlight the potential of SENTI-202 as a targeted and selective therapy for AML, offering a new avenue for overcoming the challenges posed by the heterogeneity of the AML proteomic landscape."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • FLT3 • GATA2 • IFNG • IL15 • NRAS • PDX1 • TNFA

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 (GlobeNewswire) - "Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML). Pharmacodynamic data further underscore clinical proof-of-mechanism for 'OR/NOT' Logic Gate, showing selective killing of leukemic blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs)....Senti Bio will present data from additional clinical trial participants and longer follow-up at the ASH presentations and in a live webcast during the ASH meeting in December."

P1 data • PK/PD data • Acute Myelogenous Leukemia

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia (Yahoo Finance)

Clinical • Acute Myelogenous Leukemia

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 (GlobeNewswire) - "'Our team has continued to advance SENTI-202’s clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML at the RP2D.'....'expect to release additional efficacy and durability data from our ongoing Phase 1 study before the end of the year, representing a significant milestone for our lead program.'"

P1 data • Acute Myelogenous Leukemia

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia (GlobeNewswire) - "Senti Biosciences...announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). The Phase 1 clinical trial of SENTI-202 is enrolling adult patients with relapsed or refractory ('R/R') CD33 and/or FLT3 expressing hematologic malignancies....The RP2D has been determined as Schedule I, Dose Level 2 (i.e. 1.5 x 109 CAR+ NK cells/dose) administered on Days 0,7 and 14 of 28 Day Cycles following lymphodepleting chemotherapy and the trial is actively enrolling additional R/R AML patients into an expansion cohort at the RP2D. The Company expects to report clinical data, including efficacy and durability, from the expansion cohort before year-end."

P1 data • Trial status • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia (The Manila Times) - "Senti Biosciences, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML. Additionally, the Company released a Virtual Investor 'What This Means' segment to discuss the Orphan Drug Designation for SENTI-202."

Orphan drug • Acute Myelogenous Leukemia

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 (GlobeNewswire) - "Senti Biosciences, Inc...today reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant to Senti Bio to support the ongoing clinical development of SENTI-202...for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). To date, the Company has received a total of $7.4 million of the $8.0 million available under the grant."

Financing • Acute Myelogenous Leukemia

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 (GlobeNewswire) - "Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit."

Clinical • Acute Myelogenous Leukemia • Myelodysplastic Syndrome